吉西他滨与吉非替尼联合顺铂治疗西北区非小细胞肺癌患者的疗效分析

Analysis on the Therapy Effect of Gemcitabine-Plus-Cisplatin and Gefitinib-Plus-Cisplatin Treatment on Patients with Non-Small Cell Lung Cancer

目的:比较吉西他滨与吉非替尼联合顺铂治疗非小细胞肺癌的临床有效性及安全性。方法:80例非小细胞肺癌患者根据入院顺序平分为治疗组与对照组各40例,治疗组采用吉西他滨联合顺铂治疗,对照组采用吉非替尼联合顺铂治疗,对比观察两组治疗效果及存活时间。结果:经过治疗后,治疗组无完全缓解患(CR)病例,部分缓解(PR)16例,有效率(RR)40.0%;对照组无完全缓解(CR)病例,部分缓解(PR)8例,有效率(RR)20.0%。治疗组的治疗有效率明显高于对照组,两组差异有显着性意义(P<0.05)。治疗组1年生存率为50.0%(20/40),对照组1年生存率为45.0%(18/40),两组1年生存率比较无统计学差异(P>005)。治疗组在治疗中有20例患者出现不同程度的不良反应,治疗组出现23例不同程度的不良反应。两组不良反应主要为皮疹、腹泻、转氨酶升高、皮肤水泡等。两组总的不良反应发生率与各个单项不良反应发生率相比无显着性差异,具有可比性(P>0.05)。结论:吉西他滨联合顺铂治疗非小细胞肺癌的临床有能取得更好的近期治疗效果,同时无明显不良反应,但不会提高1年生存率,值得推广应用。

Objective： To compare the effectiveness and adverse reactions of gemcitabine-plus-cisplatin and gefitinib-plus-cisplatin treatment on patients with non-small cell lung cancer. Method： 80 patients of non-small cell lung cancer were equally divided into two groups according to their admission order. The treatment group were applied with gemcitabine and cisplatin treatment, and the control group were applied with gefitinib and cisplatin treatment. Compare the therapy effect and survival rate between the two groups. Results： After treatment, there were no complete remission （CR） cases, but 16 cases in partial remission （PR） in the treatment group, with an efficiency （RR） of 40.0%; in the control group, there were also no complete remission cases but 8 cases in partial remission, with an efficiency （RR） of 20.0%. The treatment group had higher efficiency than the control group （P 〈0.05）. The one-year survival rate was 50.0% （20/40） in treatment group, and 45.0% （18/40） in control group （P〉 005）, without statistical differences. 20 cases in the treatment group had different degrees of adverse reactions, so that were 23 cases in the control group （P〉 0.05）. And the adverse reactions in the two groups included rash, diarrhea, increase of transaminase and skin vesicle and so on. There were no significant differences in the total incidence of adverse reactions and incidence of each item between the two groups. So results in this study were of comparability（P〉0.05）. Conclusion： Gemcitabine and cisplatin in the treatment of non-small cell lung cancer have better short-term effect, with no obvious side effects, but does not improve the one-year survival rate. This treatment is worth of being widely applied.